Models Can Predict Breast Cancer-Related Lymphedema
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, July 14, 2023 -- Preoperative and postoperative models are highly accurate for predicting breast cancer-related lymphedema (BCRL), according to a study published online July 12 in JAMA Surgery.
Danielle H. Rochlin, M.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a prognostic study involving women with breast cancer who underwent axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) from 1999 to 2020 to create a simple and accurate prediction model for BCRL. Data were included for 1,882 female patients (mean age, 55.6 years).
The researchers found that at a mean follow-up of 3.9 years, 11.6 percent of patients were diagnosed with BCRL. The BCRL rate was significantly higher among Black women compared with Asian, White, and other race women (22.1 percent versus 12.5, 10.1, and 14.8 percent, respectively). Accuracy for model 1 (preoperative), which included age, weight, height, race, ALND/SLNB status, any radiation therapy, and any chemotherapy, was 73.0 percent, sensitivity was 76.6 percent, specificity was 72.5 percent, and the area under the receiver operating characteristic curve (AUC) was 0.78 at a cutoff of 0.18. For model 2 (postoperative), which included age, weight, race, ALND/SLNB status, any chemotherapy, and patient-reported arm swelling, accuracy was 81.1 percent, sensitivity was 78.0 percent, specificity was 81.5 percent, and the AUC was 0.86 at a cutoff of 0.10. Higher AUCs were seen for both models on external or internal validation.
"By implementing these predictive models in a patient-facing format within clinical care, our goal is to direct patients to appropriate preoperative and postoperative interventions in a manner that balances precision and practicality," the authors write.
Two authors disclosed ties to the biopharmaceutical, medical device, and publishing industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors
FRIDAY, May 24, 2024 -- A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier...
ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy
THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a...
4-Dimensional Model Can Predict Lymph Node Metastases in Breast Cancer
THURSDAY, May 23, 2024 -- A deep learning model using tumor dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has high sensitivity for identifying lymph node...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.